Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Fusion Pharmaceuticals Inc. (FUSN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
8-K
| Quarterly results|
Docs:
|
"FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA June 30, 2023 December 31, 2022 Cash, cash equivalents and investments $ 226,519 $ 186,635 Total assets 268,286 219,064 Total liabilities 65,325 56,843 Total stockholders' equity 202,961 162,221 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Collaboration revenue $ 34 $ 570 $ 62 $ 1,155 Operating expenses: Research and development 18,994 12,076 34,871 24,737 General and administrative 7,753 7,781 16,759 16,230 Total operating expenses 26,747 19,857 51,630 40,967 Loss from operations Other income : Interest income 2,495 198 4,416 281 Interest expense Other income , net 80 64 Total other inco..." |
|
| 05/11/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
8-K
| Quarterly results|
Docs:
|
"FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA December 31, 2022 2021 Cash, cash equivalents and investments $ 186,635 $ 220,782 Total assets 219,064 252,271 Total liabilities 56,843 20,815 Total stockholders' equity 162,221 231,456 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Collaboration revenue $ 140 $ 594 $ 1,461 $ 1,440 Operating expenses: Research and development 17,607 11,811 58,895 56,357 General and administrative 6,950 6,336 30,600 27,098 Total operating expenses 24,557 18,147 89,495 83,455 Loss from operations Other income: Interest income 1,309 81 2,161 381 Interest expense — — Other income, net 63 469 Total other income, ..." |
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
8-K/A
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ... |
| 02/13/2023 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results|
Docs:
|
"FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA September 30, 2022 December 31, 2021 Cash, cash equivalents and investments $ 205,481 $ 220,782 Total assets 238,493 252,271 Total liabilities 55,351 20,815 Total stockholders' equity 183,142 231,456 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Collaboration revenue $ 166 $ 325 $ 1,321 $ 846 Operating expenses: Research and development 16,551 12,684 41,288 44,546 General and administrative 7,420 7,156 23,650 20,762 Total operating expenses 23,971 19,840 64,938 65,308 Loss from operations Other income: Interest income, net 190 107 220 300 Other income, net 27 406 Total other income..." |
|
| 08/09/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 06/09/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/13/2022 |
8-K
| Other Events Interactive Data |
| 04/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/17/2022 |
8-K
| Quarterly results |
| 11/09/2021 |
8-K
| Quarterly results |
| 08/13/2021 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 08/10/2021 |
8-K
| Quarterly results |
| 07/23/2021 |
8-K/A
| Quarterly results |
| 07/02/2021 |
8-K
| Other Events |
| 06/07/2021 |
8-K
| Quarterly results |
| 06/03/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results |
| 04/02/2021 |
8-K
| Quarterly results |
| 04/02/2021 |
8-K
| Quarterly results |
| 03/25/2021 |
8-K
| Quarterly results |
| 03/02/2021 |
8-K
| Quarterly results |
| 02/12/2021 |
8-K
| Quarterly results |
| 11/10/2020 |
8-K
| Quarterly results |
| 11/03/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 30, 2020 FUSION PHARMACEUTICALS INC. Canada 001-39344 Not Applicable 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 799-0891 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursu...",
"Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors Hamilton, ON & Boston, MA, November 2, 2020 - Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Barbara Duncan, former chief financial officer of Intercept Pharmaceuticals, Inc. and member of several boards of directors within the biotechnology industry, as chairperson of the Fusion Board of Directors. Ms. Duncan brings to the board more than 25 years' experience in the biopharmaceutical industry. She replaces Damian Lamb as Fusion's chairperson. “Barbara's breadth and depth of industry, director and financial knowledge will be invaluable to Fusion as we solidify our positi..." |
|
| 11/02/2020 |
8-K
| Investor presentation |
| 08/11/2020 |
8-K
| Quarterly results |
| 06/30/2020 |
8-K
| Quarterly results |
|
|